Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
Dummer R, Hauschild A, Santinami M, Atkinson V, Mandalà M, Kirkwood JM, Chiarion Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Gasal E, Tan M, Long GV, Schadendorf D.
Dummer R, et al.
N Engl J Med. 2020 Sep 17;383(12):1139-1148. doi: 10.1056/NEJMoa2005493. Epub 2020 Sep 2.
N Engl J Med. 2020.
PMID: 32877599
Free article.
Clinical Trial.
No clinically meaningful between-group difference in the incidence or severity of serious adverse events was reported during the follow-up period. ...
No clinically meaningful between-group difference in the incidence or severity of serious adverse events was reported during the foll …